TABLE 3.
Antibody neutralization of JP-III-48-activated HIV-1JR-FL infection of CD4-negative Cf2Th-CCR5 cellsa
| Antibody/Env ligand | gp120 specificity | IC50 (nM) |
||
|---|---|---|---|---|
| HIV-1JR-FL + 25 μM JP-III-48 | AMLV |
|||
| +25 μM JP-III-48 | −25 μM JP-III-48 | |||
| 17b | CD4 induced | <3.3 | >200 | >200 |
| 19b | V3 | <3.3 | >200 | >200 |
| 2G12 | Outer domain glycan | <3.3 | >200 | >200 |
| F105 | CD4-binding site | >200 | >200 | >200 |
| VRC01 | CD4-binding site | <3.3 | >200 | >200 |
| VRC03 | CD4-binding site | <3.3 | >200 | >200 |
| PG9 | V2 quaternary | >200 | >200 | >200 |
| sCD4 | CD4-binding site | >200 | >200 | >200 |
a
HIV-1 pseudotyped with the HIV-1JR-FL or AMLV Env was incubated with 25 μM JP-III-48 for 5 min at 37°C and then for 15 min at 37°C with different concentrations of antibodies or sCD4. The virus–JP-III-48–antibody mixtures were then spinoculated onto Cf2Th-CCR5 cells. After 48 h at 37°C, the cells were lysed, and the cell lysates were assayed for luciferase activity. The mean values for luciferase activity were derived from triplicate samples. The level of luciferase activity relative to that seen in the absence of antibody or sCD4 was used to calculate the level of infection. The IC50s of the antibodies and sCD4 are reported.